Mark S. Cohen Chair of the Life Science Practice Group of Pearl Cohen Zedek Latzer represents Prolor Biotec in its patent and licensing matters, and represented PROLOR on patent and licensing matters as related to the OPKO purchase of PROLOR.
PROLOR is a biopharmaceutical company focused on developing and commercializing longer-acting proprietary versions of already approved therapeutic proteins. The all-stock transaction is valued at approximately $480 million.
